Searchable abstracts of presentations at key conferences in endocrinology

ea0031cmw2.4 | How Do I Do It? | SFEBES2013

How do I manage the pregnant patient with a prolactinoma?

Bevan John S

There are two issues: i) dopamine agonist (DA) safety for mother and baby, and ii) risk of oestrogen-induced prolactinoma enlargement. Bromocriptine (BC) and Cabergoline (CAB) are both safe for ovulation induction but the safety database is larger for BC (6239 pregnancies) than for CAB (789). Neither drug causes increases in miscarriage, premature delivery, multiple births or congenital malformations, compared to data for normal pregnancy. Risk of symptomatic tumour enlargemen...

ea0025pl9 | Clinical Endocrinology Trust Lecture | SFEBES2011

Pituitary tumours: the goal is shrinking!

Bevan John S

In 2011 is the 40th anniversary of prolactin (PRL) characterisation as a distinct hormone. Only 30 years ago most patients with large pituitary tumours received primary surgery (often transcranial) followed by routine radiotherapy – treatments associated with significant morbidity and hypopituitarism. Much therapeutic progress has been made; effective medical treatments now exist for many pituitary tumour subtypes, particularly the use of long-acting dopamine agonists (DA...

ea0025pl9biog | Clinical Endocrinology Trust Lecture | SFEBES2011

Clinical Endocrinology Trust Lecture

Bevan John S

John S Bevan, Department of Endocrinology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB25 2ZN, UK. AbstractJohn S Bevan is senior Consultant Endocrinologist at Aberdeen Royal Infirmary and Honorary Professor of Endocrinology at Aberdeen University. He qualified MB ChB, with Honours, from Edinburgh University in 1978 and his clinical training in Medicine & Endocrinology took place in Edinburgh, Oxford and Ca...

ea0049gp191 | Pituitary & endocrine Tumours | ECE2017

GH and IGF-1 levels at 12 weeks predict long-term responses to lanreotide Autogel in treatment-naïve acromegalic patients: post-hoc analyses from the PRIMARYS study

Caron Philippe , Petersenn Stephan , Houchard Aude , Sert Caroline , Bevan John S

Background: In PRIMARYS, lanreotide Autogel (LAN) 120 mg/28 days reduced tumour volume (TV), and GH/IGF-1 levels in patients with GH-secreting macroadenomas. In post-hoc analyses, we investigated predictive factors for treatment responses.Methods: PRIMARYS, a 48-week, international, open-label study, involved 90 treatment-naïve patients with GH-secreting macroadenomas receiving LAN. Factors predictive for hormonal control (HC; GH ≤2.5...

ea0034p13 | Bone | SFEBES2014

Mutational analysis of the adaptor protein 2 sigma subunit (AP2S1) gene: search for autosomal dominant hypocalcaemia type 3 (ADH3)

Rogers Angela , Nesbit M Andrew , Hannan Fadil M , Howles Sarah A , Cranston Treena , Allgrove Jeremy , Bevan John S , Bano Gul , Brain Caroline , Datta Vipan , Hodgson Shirley V , Izatt Louise , Millar-Jones Lynne , Pearce Simon H , Robertson Lisa , Selby Peter L , Shine Brian , Snape Katie , Warner Justin , Thakker Rajesh V

Familial hypocalciuric hypercalcaemia types 1, 2, and 3 (FHH1, FHH2, and FHH3) are caused by loss-of-function mutations of the calcium-sensing receptor (CaSR), G-protein subunit α11 (Gα11) and adaptor protein 2 sigma subunit (AP2σ), respectively; whilst autosomal dominant hypocalcaemia types 1 and 2 (ADH1 and ADH2) are due to gain-of-function mutations of CaSR and Gα11, respectively. We therefore hypothesised that gain-of-function AP2σ mutations may re...